Category: C.R. Bard
C. R. Bard is reportedly close to settling a suit filed in a West Virginia federal court by a woman who claimed she was injured by the company's pelvic-mesh device, Avaulta Plus.
C.R. Bard (NYSE:BCR) is reportedly close to settling a suit filed in West Virginia federal court by a woman who claimed she was injured by the company's pelvic-mesh device, Avaulta Plus.
C.R. Bard inks a deal for Boston Scientific to distribute its Lutonix drug-eluting balloon in the U.S.
The federal judge overseeing some 70,000 pelvic mesh product liability lawsuits urges the plaintiffs and the medical device company defendants to settle.
(Reuters) — A U.S. judge Thursday urged transvaginal mesh device makers and the women suing them to work harder to resolve their 10s of thousands of lawsuits in 1 of the biggest U.S. mass torts in history.
C. R. Bard reports a lower fourth-quarter profit, due largely to hefty gains recorded for a patent infringement suit against W.L. Gore & Associates and the sale of its electrophysiology unit in 2013.
A tough comparison with the year-ago quarter pushed C.R. Bard's (NYSE:BCR) 4th-quarter profits down 80%, due largely to hefty gains from patent infringement suit and the 2013 sale of its electrophysiology unit.
Here's a look at some of the top legal news stories for medical device companies this week: Appeals court puts Gore on the hook for $1B in damages to Bard; Bard loses bid to delay pelvic mesh cases over judge's comments; Johnson & Johnson: Women asked to lie for pelvic mesh payoffs; BD notches partial win in $352m anti-trust loss to Retractable Technologies
A federal appeals court today ruled that W.L. Gore & Assoc. owes C.R. Bard $1 billion in penalties and damages for infringing a stent graft patent.
A federal judge shoots down a bid by C.R. Bard to delay a raft of pelvic mesh product liability trials, ruling that Bard failed to show that his comments tainted the jury pool.